Table 1.
List of clinical trials of mRNA vaccines applying vectors for cancer therapy.
| Vaccine type (Vector) | Name | mRNA encoding | Disease | Administration route | Start year (Status) |
Phase | ClinicalTrials.gov identifier |
|---|---|---|---|---|---|---|---|
| Lipo-MERIT | BNT111 | NY-ESO-1, MAGE-A3, tyrosinase, TPTE |
Melanoma | i.v. | 2015 (Active, not recruiting) |
Phase I | NCT02410733 |
| Lipo-MERIT | BNT111 | NY-ESO-1, MAGE-A3, tyrosinase, TPTE | Unresectable stage III/IV melanoma | i.v. | 2021 (Recruiting) |
Phase II | NCT04526899 |
| Lipo-MERIT | BNT112 | 5 PC TAAs | Prostate cancer (PC) | i.v. | 2019 (Recruiting) |
Phase I/II | NCT04382898 |
| Lipo-MERIT | BNT113 | Fixed combination of shared cancer antigens | Unresectable recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) | i.v. | 2021 (Recruiting) |
Phase II | NCT04534205 |
| Lipo-MERIT | BNT115 | 3 OC TAAs | Ovarian cancer (OC) | i.v. | 2019 (Active, not recruiting) |
Phase I | NCT04163094 |
| Lipo-MERIT | BNT116 | TAAs | Non-small cell lung cancer (NSCLC) | i.v. | 2022 (Recruiting) |
Phase I | NCT05142189 |
| Lipo-MERIT | BNT116 | TAAs | Advanced NSCLC | i.v. | 2023 (Recruiting) |
Phase II | NCT05557591 |
| Lipo-MERIT | RO7198457 | 20 neoantigens | Melanoma, NSCLC, bladder/colorectal/renal cancers, breast cancer, head and neck cancer (HNC), other solid cancers | i.v. | 2017 (Active, not recruiting) |
Phase I | NCT03289962 |
| Lipo-MERIT | RO7198457 | 20 neoantigens | Advanced melanoma | i.v. | 2019 (Active, not recruiting) |
Phase II | NCT03815058 |
| Lipo-MERIT | RO7198457 | 20 neoantigens | Colorectal cancer stage II/III | i.v. | 2021 (Recruiting) |
Phase II | NCT04486378 |
| Lipo-MERIT | RO7198457 | 20 neoantigens | Pancreatic cancer | - | 2019 (Active, not recruiting) |
Phase I | NCT04161755 |
| Lipoplex | IVAC_W_bre1_uID, IVAC_W_bre1_uID/IVAC_M_uID | TAAs plus p53, 20 neoantigens | Triple-negative breast cancer (TNBC) | i.v. | 2016 (Active, not recruiting) |
Phase I | NCT02316457 |
| Lipoplex | BNT211 | CLDN6 | Solid tumors | i.v. | 2020 (Recruiting) |
Phase I/II | NCT04503278 |
| LNP | mRNA-2416 | Human OX40L | Relapsed/Refractory solid tumors, ovarian cancer | i.t. | 2017 (Terminated) |
Phase I/II | NCT03323398 |
| LNP | mRNA-2752 | Human OX40L, IL-23, IL-36γ |
Relapsed/Refractory solid tumor malignancies or lymphoma | i.t. | 2018 (Recruiting) |
Phase I | NCT03739931 |
| LNP | mRNA-4157 | ~20 neoepitopes | Solid tumors | i.m. | 2017 (Active, not recruiting) |
Phase I | NCT03313778 |
| LNP | mRNA-4157 | ~20 neoepitopes | Melanoma | i.v. | 2019 (Recruiting) |
Phase II | NCT03897881 |
| LNP | V941 | Kirsten rat sarcoma viral oncogene mutated proteins | Neoplasms, carcinoma, NSCLC, pancreatic neoplasms, colorectal neoplasms | i.m. | 2019 (Completed) |
Phase I | NCT03948763 |
| LNP | NCI4650 | Neoantigens | Melanoma, colon/ gastrointestinal/ genitourinary/ hepatocellular cancers | i.m. | 2018 (Terminated) |
Phase I/II | NCT03480152 |
| Protamine | CV9104 | Prostate-specific antigens | Prostate cancer | i.d. | 2012 (Terminated) |
Phase I/II | NCT01817738 |
| Protamine | CV9104 | Prostate-specific antigens | Prostate carcinoma | i.d. | 2014 (Terminated) |
Phase II | NCT02140138 |
| Protamine | CV9201 | MAGE-C1, MAGE-C2, NY-ESO-1, survivin, 5T4 | NSCLC | i.d. | 2009 (Completed) |
Phase I/II | NCT00923312 |
| Protamine | CV9202 | 6 different NSCLC associated antigens | NSCLC | i.d. | 2013 (Terminated) |
Phase I | NCT01915524 |
| Protamine | CV9202 | NY-ESO-1, MAGE-C1, MAGE-C2, 5T4, survivin, MUC1 | NSCLC | i.d. | 2017 (Completed) |
Phase I/II | NCT03164772 |